Moderna 4Q Revenues: $2.8 billion (-43%) 4Q Earnings: $217 million (earnings were $1.5 billion 4Q22) FY Revenues: $6.8 billion (-183%) FY Loss: $4.7 billion (earnings were $8.4 billion in 2022) Comments: Results impacted by decline in COVID-19 vaccine sales. The company reported $2.8 billion in Spikevax (COVID-19 vaccine) sales in the quarter, which includes $0.8 billion of U.S. sales and $2 billion of international sales. For the year sales were $6.7 billion, down 64%. Moderna had 48% cumu...